Dacomitinib did not improve overall survival compared with placebo ( median 683 months [ 95 % CI 608-749 ] for dacomitinib vs 631 months [ 532-752 ] for placebo ; hazard ratio [ HR ] 100 [ 95 % CI 083-121 ] ; p = 0506 ) .